The Rise of Direct-to-Consumer: Pharma's Path Around the Formulary
As payer restrictions tighten and biosimilar competition intensifies, manufacturers are rethinking how they reach patients. This infographic, drawn from MMIT and The Dedham Group's 2026 State of Patient Access Survey of 285 pharma and biotech leaders, examines why direct-to-consumer (DTC) and cash-pay models are gaining ground.
Download the Infographic
Learn which biosimilar pressures manufacturers feel most acutely, from provider purchasing shifts to formulary exclusion risk.
Discover where DTC programs stand today across therapeutic areas, from migraine, allergies and diabetes to oncology.
Understand how DTC programs can help manufacturers preserve the patient relationship outside of formulary constraints.